DBDagmar von Bubnoff

Dagmar von Bubnoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dagmar von Bubnoff has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Differential Expression of Toll-Like Receptor 2 on Dendritic Cells from Asymptomatic and Symptomatic Atopic Donors

    by D. von Bubnoff, U. Sell, S. Arriens, S. Specht, A. Hoerauf, T. Bieber

    Background: Early microbial exposure may reduce the risk for developing allergies on an atopic genetic background. Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns of microbes and modulate innate and adaptive immunity. Different expression of TLRs in symptomatic and asymptomatic atopic donors may contribute to the development of allergic disease. Methods: Monocytes and monocyte-derived dendritic cells (DCs) from symptomatic (n = 12) and asymptomatic atopic donors (n = 11), healthy nonatopics (n = 14) and from patients with psoriasis (n = 13) were analyzed for their expression of TLR2, TLR4 and TLR9 by real-time PCR. Results: Monocytes did not show any differences in TLR2, TLR4 and TLR9 expression between the 4 groups. In contrast, DCs from asymptomatic donors showed an enhanced expression of TLR2 over DCs from nonatopics (p = 0.038) and just failed to reach significance when compared to symptomatic atopic patients (p = 0.060). TLR2 expression kinetics from monocytes to monocyte-derived DCs showed sustained expression of TLR2 in DCs only from asymptomatic donors but downregulation in the other groups. In DCs from symptomatic atopic donors, the expression of TLR2 correlated significantly with total IgE values in the serum (p = 0.01994). Conclusion: Differential expression and functional regulation of TLR2 expression by DCs from symptomatic and asymptomatic atopic donors may be important for the manifestation of allergic disease. Increased and sustained TLR2 expression on DCs, possibly as a result of an increased exposure to microorganisms or as a mechanism enhancing the sensitivity of microbe detection, may be of functional importance for the maintenance of clinical unresponsiveness toward allergens.


  • Open Access

    The indoleamine 2,3‐dioxygenase (IDO) pathway controls allergy

    by D. von Bubnoff, T. Bieber

    A series of recent studies have demonstrated that the immunoregulatory pathway of tryptophan catabolism, initiated by the enzyme indoleamine 2,3‐dioxygenase (IDO), is a critical participant in allergic inflammation. Originally known for its regulatory function during pregnancy and during chronic inflammation in tumorigenesis and infection, the activity of IDO seems to positively modify the inflammatory state of atopy or allergy. The tryptophan degradation pathway is important for tolerance induction during systemic allergen immunotherapy. Here, we focus on recent findings that establish the IDO pathway as central to allergic inflammation.


  • Indoleamine 2,3‐dioxygenase expression in early keratocyte neoplasia of the lower lip correlates to the degree of cell atypia

    by Dagmar von Bubnoff, Sabine Zahn, Jörg Wenzel, Helene Wilms, Thomas Bieber, Matthias Lüftl

    Actinic cheilitis (AC) is an early keratocyte neoplasia with inflammation that occurs in the lip vermillion with the potential to develop into invasive squamous cell carcinoma (SCC). The expression of the intracellular enzyme indoleamine 2,3‐dioxygenase (IDO) by antigen‐presenting cells and/or tumor cells has been described to arrest T cell proliferation by degrading the essential amino acid tryptophan from the environment. The expression of IDO in AC may support cancer progression by inhibiting T cell‐mediated rejection responses. The aim of this study was to identify the cellular nature and extent of IDO expression in early keratocye neoplasia of the lower lip (n = 25), and to correlate IDO expression to the severity of epithelial atypia (KIN I°‐ KIN III°) and to the extent of actinic inflammation. The expression of IDO was analyzed together with expression markers for T‐cells (CD3), myeloid DCs (S100, CD11c), macrophages (CD68, CD11c), and Langerhans cells (CD1a) by immunohistochemistry and immunofluorescence analysis. Analyses showed that IDO was expressed in myeloid S100+CD11c+ DCs. The expression of IDO correlated significantly with the degree of epithelial atypia (P = 0.0005) but not to the extent of inflammation (P = 0.4283). Expression of IDO in early atypic skin epithelial conditions might be a predictor to promote carcinogenesis.


  • Indoleamine 2,3-dioxygenase–expressing myeloid dendritic cells and macrophages in infectious and noninfectious cutaneous granulomas

    by Dagmar von Bubnoff, Marina Scheler, Helene Wilms, Jörg Wenzel, Nikolas von Bubnoff, Georg Häcker, Joachim Schultze, Alexey Popov, Paul Racz, Thomas Bieber, et al.


  • Human myeloid dendritic cells are refractory to tryptophan metabolites

    by Dagmar von Bubnoff, Helene Wilms, Marina Scheler, Manuela Brenk, Susanne Koch, Thomas Bieber


  • Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma.

    by Melanie Alice Kuales, Jörg Wenzel, Monika-Hildegard Schmid-Wendtner, Thomas Bieber, Dagmar Von Bubnoff

    The prevalence of squamous cell carcinoma of the lower lip (SCC-LL) is increasing worlwide. The expression of the enzyme indoleamine 2,3-dioxygenase (IDO) by antigen-presenting cells and/or tumor cells leads to tumor escape by inhibiting T cell-mediated rejection responses. The aim of this study was to determine the expression of IDO in SCC-LL. IDO-expression was analyzed in 47 SCC-LL, together with the expression of markers of T-cells (CD3), myeloid DCs (S100, CD11c), macrophages (CD68, CD11c), Langerhans cells (CD1a, Langerin (CD207)), plasmacytoid DCs (CD123), and regulatory T cells (Foxp3) by immunohistochemistry and immunofluorescence analysis. Twelve specimens out of 47 LL-SCCs contained cells that expressed IDO. IDO-positivity was strongly associated with the intensity of the cancer-associated infiltrate (P=0.0007). IDO-positive cells are located right along the border between the developing tumor and the inflammatory infiltrate. Immunofluorescence stainings showed that CD11c+S100+CD68- dendritic cells (DCs) express IDO in SCC-LL. IDO expression in LL-SCC may aid immune escape and chronic inflammation to promote cancer progression. Inhibition of IDO might be a therapeutic strategy to increase the anti-tumor immune response in SCC-LL.


  • Open Access

    Identification of IDO-Positive and IDO-Negative Human Dendritic Cells after Activation by Various Proinflammatory Stimuli

    by Dagmar Von Bubnoff, Marina Scheler, Helene Wilms, Rolf Fimmers, Thomas Bieber

    Dendritic cells (DCs) can induce tolerance or immunity. We identified and characterized an IDO-expressing and an IDO-negative human DC population after stimulation by various proinflammatory stimuli. IDO expression was strongly dependent on the maturation status of the cells (CD83-positive cells only). The two DC subpopulations remained IDO positive and IDO negative, respectively, over a time period of at least 48 h. IDO enzyme activity of human DCs was highest during stimulation by strongly maturation-inducing TLR ligands such as highly purified LPS (TLR4 ligand) or polyriboinosinic-polyribocytidilic acid (TLR3 ligand); factors of the adaptive immune system such as IFN-γ, a mixture of cytokines, and IFN-α had lesser stimulatory capacity for IDO induction and activity. After stimulation with CD40L, IDO-positive DCs expressed significantly increased levels of B7 family molecules such as CD40, CD80, CD86, ICOS ligand, as well as PD-L1 (B7-H1) and PD-L2 (B7-DC) compared with the IDO-negative DC subset. At the same time, the inhibitory receptors Ig-like transcripts 3 and 4 were significantly downregulated on IDO-positive cells. Functionally, IDO-positive DCs produced significantly more IL-1β and IL-15 and less IL-10 and IL-6 than the IDO-negative subset after CD40L stimulation. These results show that IDO expression is associated with a distinctive phenotype and functional capacity in mature DCs. It seems likely that the IDO-positive DC subset possesses a regulatory function and might skew a T cell response toward tolerance.


  • Natural Killer Cells and the Skin

    by Dagmar von Bubnoff

  • Human Epidermal Langerhans Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase

    by Dagmar von Bubnoff, Huguette Bausinger, Heike Matz, Susanne Koch, Georg Häcker, Osamu Takikawa, Thomas Bieber, Daniel Hanau, Henri de la Salle


  • Asymptomatic atopy is associated with increased indoleamine 2,3‐dioxygenase activity and interleukin‐10 production during seasonal allergen exposure

    by D. Von Bubnoff, R. Fimmers, M. Bogdanow, H. Matz, S. Koch, T. Bieber

    Summary: Background Indoleamine 2,3‐dioxygenase (IDO) is a tryptophan (TRP)‐catabolizing enzyme with regulatory effects on T cells. T cell inhibition is achieved through both TRP depletion and TRP metabolite accumulation in specific local tissue microenvironments. The expression of IDO activity by different types of antigen‐presenting cells (APCs) has been shown to play a role in many instances of immunoregulation and tolerance induction. Induction of IDO after the engagement of the high‐affinity receptor for IgE, FcɛRI, on atopic monocytes has been suggested to regulate T cell responses in atopic disorders. Interleukin‐10 (IL‐10), a cytokine known for its down‐regulatory functions in the immune system, has recently been associated with the stable expression of IDO in mature tolerogenic dendritic cells.Objective This study was devised to understand the role of systemic IDO and IL‐10 in the prevention of clinical apparent allergy.Methods The concentration of TRP and the break‐down product kynurenine were measured by high‐performance liquid chromatography in‐ and off‐season in sera from patients with seasonal allergic rhinitis (n=12) and from clinically asymptomatic atopic patients sensitized to specific aeroallergens (n=12). Non‐atopic (NA) individuals (n=12) served as control. The concentration of plasma IL‐10 was determined in parallel from these donors by ELISA in‐ and off‐season.Results In clinically unresponsive but aeroallergen‐sensitized atopic individuals significantly higher systemic activity of IDO and increased plasma IL‐10 levels were found during allergen exposure but not off‐season compared to symptomatic atopic individuals with allergic rhinitis and NA individuals.Conclusion Enhanced systemic IDO activity as well as increased systemic levels of IL‐10 may contribute to the containment of allergic T cell responses and could be involved in the maintenance of a state of clinical unresponsiveness.